Estrella Immunopharma (ESLA) to Release Quarterly Earnings on Wednesday

Estrella Immunopharma (NASDAQ:ESLA) is expected to be issuing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Estrella Immunopharma Trading Down 4.1%

Shares of ESLA stock opened at $1.18 on Monday. The stock has a 50 day simple moving average of $1.28 and a 200-day simple moving average of $1.47. The company has a market cap of $44.57 million, a price-to-earnings ratio of -3.47 and a beta of 0.55. Estrella Immunopharma has a 12-month low of $0.73 and a 12-month high of $3.15.

Wall Street Analysts Forecast Growth

ESLA has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Wednesday, January 28th. D. Boral Capital reiterated a “buy” rating and issued a $8.00 price target on shares of Estrella Immunopharma in a report on Monday, February 9th. Finally, Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Estrella Immunopharma currently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Investors Weigh In On Estrella Immunopharma

A number of hedge funds and other institutional investors have recently modified their holdings of ESLA. Renaissance Technologies LLC raised its position in shares of Estrella Immunopharma by 1,045.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after buying an additional 111,779 shares during the last quarter. Geode Capital Management LLC grew its stake in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after acquiring an additional 8,318 shares during the period. Marshall Wace LLP acquired a new position in Estrella Immunopharma in the 4th quarter valued at $88,000. XTX Topco Ltd lifted its stake in shares of Estrella Immunopharma by 376.9% during the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the period. Finally, State Street Corp lifted its stake in shares of Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares during the period. 0.35% of the stock is currently owned by hedge funds and other institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.